Kali Therapeutics licenses Sanofi asset

Kali Therapeutics has entered into a worldwide exclusive license agreement with Sanofi for a next-generation tri-specific T-cell engager. This therapy is being developed for autoimmune diseases. The agreement grants Kali Therapeutics the rights to advance this promising biologic candidate, potentially accelerating its path to clinical development and market. This collaboration leverages Sanofi's expertise and pipeline while empowering Kali Therapeutics to pursue innovative treatments for complex autoimmune conditions, marking a significant step for both companies.